ArticleBMC medicine2026
Frozen melanoma tissues yield extracellular vesicles with preserved diagnostic and immunogenic properties.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracellular vesicles (EVs) isolated from tumor tissues carry disease-associated proteins and surface antigens, making them promising candidates for cancer diagnostics and immunotherapy. For EV-based approaches to reach clinical application, it is essential that functional EVs can be obtained from clinically accessible materials, including cryopreserved tumor tissues stored in biobanks. Whether cryopreservation alters EV integrity and function remains unclear. This study evaluates whether EVs derived from cryopreserved tumor tissues retain key molecular and biological properties required for diagnostic and therapeutic use.
methodsEVs were isolated from human metastatic melanoma tissues processed immediately after surgical resection (fresh) or after storage at - 80 °C (frozen), using a protocol consistent with standard biobank procedures. EV isolation was performed through ultracentrifugation followed by an iodixanol density cushion. The resulting EVs were characterized by transmission electron microscopy, nanoparticle tracking analysis, and mass spectrometry to assess EV morphology, purity, and molecular composition. The diagnostic potential was evaluated by examining the presence of previously identified cancer-associated membrane proteins. Furthermore, therapeutic potential was assessed in vivo by co-administering EVs from fresh or frozen melanoma tissues with synthetic bacterial vesicles and evaluating their effects on tumor growth in melanoma-bearing mice.
resultsEVs from fresh and frozen tissues showed similar morphology, size distribution, yield, and purity. Moreover, the protein composition, including cancer-associated markers such as MT-CO2, COX6c, SLC24A22, HLA-DR, and Erlin2, was highly consistent between EVs derived from fresh and frozen tissues, with no relevant enrichment of intracellular or mitochondrial contaminants in frozen-derived EVs. Functionally, EVs from cryopreserved tissues combined with synthetic bacterial vesicles significantly inhibited tumor progression in vivo, demonstrating antitumor effects comparable to those of EVs from fresh tissues.
conclusionsOur results validate cryopreserved tissues as a reliable source of functional EVs, comparable to fresh tissues. This supports the potential use of existing biobanks for retrospective EV-based biomarker discovery and functional research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.